First Time Loading...
N

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707

Watchlist Manager
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Watchlist
Price: 12.29 CNY -5.24% Market Closed
Updated: Jun 17, 2024
Have any thoughts about
Nanjing King-friend Biochemical Pharmaceutical Co Ltd?
Write Note

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Other Equity Peer Comparison

Comparables:
H
3692
600436
600276
000538
S
688506

Competitive Other Equity Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
N
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Other Equity
ÂĄ55.9m
CAGR 3-Years
-28%
CAGR 5-Years
80%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Equity
ÂĄ136.9m
CAGR 3-Years
N/A
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Equity
ÂĄ1.7m
CAGR 3-Years
-82%
CAGR 5-Years
-62%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Equity
ÂĄ19.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Equity
-ÂĄ33.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other Equity
ÂĄ1.4m
CAGR 3-Years
-23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Other Equity?
Other Equity
55.9m CNY

Based on the financial report for Mar 31, 2024, Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Other Equity amounts to 55.9m CNY.

What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Other Equity growth rate?
Other Equity CAGR 5Y
80%

Over the last year, the Other Equity growth was 9%. The average annual Other Equity growth rates for Nanjing King-friend Biochemical Pharmaceutical Co Ltd have been -28% over the past three years , 80% over the past five years .